New opportunities for using transdermal forms of estradiol in ART programs

of this review is to summarize the accumulated data on the use of estradiol transdermal gel in the form of a bottle with a pump-dispenser Oestrogel® in the treatment of "thin" endometrium and in assisted reproductive technologies (ART) programs. "Thin" is the endometrium with thickness on ultrasound not exceeds 7 mm during ovulation and is characterized by complete or partial absence of conditions for ovum implantation. Endometrial thickness of 8 mm is referred to as hypoplastic endometriopathy. This endometrium thickness is used to predict the possibility of pregnancy in ART cycles. Estrogen and progesterone are the two main hormones responsible for morphological changes in the endometrial structure during the menstrual cycle. Estradiol promotes the expression of progesterone receptors, thus increasing the tissue sensitivity to progesterone. Today in Ukraine, oral and transdermal estrogens are widely used in ART programs. Transdermal estrogens are preferred due to their lack of a primary hepatic transit effect, which provides a higher safety profile compared to oral forms. A number of researches have been study the effectiveness of the Oestrogel®. It has been established that this drug is highly effective and safe for preparing patients for cryo-transfer of thawed embryos in ART programs. It has also been proven that the efficacy of estradiol transdermal gel in terms of pregnancy rate in patients treated in ART programs with gonadotropic releasing hormone antagonists is comparable to that of oral estradiol valerate and a transdermal patch. In another study, the frequency of miscarriages was significantly lower in patients treated with Oestrogel® compared with patients in the oral estradiol valerate group. Long-term pregnancy and live birth rates were also statistically significantly higher in the transdermal estradiol group. Conclusion. The estrogen drug Oestrogel® is an effective in improving the indicators of prolonged pregnancy and live birth. It can be effectively used for the treating "thin" endometrium and ART programs.

- Orazov, M.R., Radzinskij, V.E., Khamoshina, M.B., et al. “Thin” endometrium - modern view of the problem”. Farmateka 6 (2018): 15-22. DOI: 10.18565/pharmateca.2018.6.15-22 - Kasius, A., Smit, J.G., Torrance, H.L., et al. “Endometrial thickness, and pregnancy rates after IVF: a systematic review and meta-analysis.” Hum Reprod Update 20.4 (2014): 530–41. DOI: 10.1093/humupd/dmu011 - Du, J., et al. “The effect of icariin for infertile women with thin endometrium.” Medicine 99: 12 (2020): e19111. DOI: 10.1097/MD.0000000000019111 - Оразов, М.Р., Радзинский, В.Е., Локшин, В.Н. Бесплодный брак: версии и контраверсии: науч. издание / Радзинский, В.Е., Оразов, М.Р., Локшин, В.Н. [и др.]; ред. В. Е. Радзинский. – Москва: ГЭОТАР-Медиа, 2019. – 403 с. - Mahajan, N., Sharma, S. “The endometrium in assisted reproductive technology: How thin is thin?” J Hum Reprod 9 (2016): 3–8. - Bosch, E., Broer, S., Griesinger, G., et al. “ESHRE guideline: ovarian stimulation for IVF/ICSI.” Hum Reprod Open 2020(2): hoaa009. DOI: 10.1093/hropen/hoaa009 - Encyclopedia of Toxicology (Second Edition), 2005. Available from: [https://doi.org/10.1016/B0-12-369400-0/00838-3]. - Scott, R.T. Jr, Ross, B., Anderson, C., Archer, D.F. “Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol.” Obstetrics and Gynecology 77.5 (1991): 758–64. - Instructions for the medical use of the drug Oestrogel. - Koloda, Y.A., Anshina, M.B. “Estradiol hemihydrate in a dosage form of a transdermal gel in patients in programs of assisted reproductive technologies in cryoprotocols using their own or donor embryos (results of an open multicenter non-interventional study).” Reproduction problems 25.6 (2019): 51–57. Available from: [https://doi.org/10.17116/repro20192506151]. - Scheffer, J.B., Scheffer, B.B., Carvalho, R.F., et al. “A comparison of the effects of three luteal phase support protocols with estrogen on in vitro fertilization-embryo transfer outcomes in patients on a GnRH antagonist protocol.” JBRA Assist Reprod 23.3 (2019): 239–45. DOI: 10.5935/1518-0557.20190012 - Shahrokh Tehraninejad, E., Kabodmehri, R., Hosein Rashidi, B., et al. “ Trans dermal estrogen (Oestrogel) for endometrial preparation in freeze embryo transfer cycle: An RCT.” Int J Reprod Biomed 16.1 (2018): 51–56. - Fatemi, H.M., Popovic-Todorovic, B., Ameryckx, L., et al. “ In vitro fertilization pregnancy in a patient with proven chronic endometritis.” Fertil Steril 91 (2009): 9–11. - Puente, E., Alonso, L., Laganà, A.S., et al. “ Chronic Endometritis: Old Problem, Novel Insights and Future Challenges.” Int J Fertil Steril 13.4 (2020): 250–256. DOI: 10.22074/ijfs.2020.5779 - Kasius, J.C., Broekmans, F.J.M., Sie-Go, D.M.D.S., et al. “ The reliability of the histological diagnosis of endometritis in asymptomatic IVF cases: a multicenter observer study.” Hum Reprod 27 (2012): 153–8. - Bashiri, A., Halper, K.I., Orvieto, R. “ Recurrent Implantation Failure-update overview on etiology, diagnosis, treatment and future directions.” Reprod Biol Endocrinol 16.121 (2018). - Afyan, A.I., Dolgushina, N.V. “ Thin endometrium in the clinic of assisted reproductive technologies (literature review).” Gynecology 5 (2014): 78–83. - Chi, Y., He, P., Lei, L., et al. “ Transdermal estrogen gel and oral aspirin combination therapy improves fertility prognosis via the promotion of endometrial receptivity in moderate to severe intrauterine adhesion.” Mol Med Rep 17.5 (2018): 6337–44. DOI: 10.3892/mmr.2018.8685. Epub 2018 Mar 6 - Liu, S.M., Zhou, Y.Z., Wang, H.B., et al. “ Factors Associated with Effectiveness of Treatment and Reproductive Outcomes in Patients with Thin Endometrium Undergoing Estrogen Treatment.” Chin Med J (Engl) 128.23 (2015): 3173–77. DOI: 10.4103/0366-6999.170258 Downloads Published How to Cite Issue Section License Copyright (c) 2021 В.В. Котлік, М.І. Грицько This work is licensed under a Creative Commons Attribution 4.0 International License. Authors who publish with this journal agree to the following terms: - Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. - Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.